We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 12, 2022

Radiographic Paradoxical Response in Patients With mCRPC Treated With New-Generation Anti-Androgens

The Prostate


Additional Info

The Prostate
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis
Prostate 2022 Sep 11;[EPub Ahead of Print], J Alamiri, CJ Britton, ME Ahmed, JR Andrews, JL Higa, A Dundar, RJ Karnes, E Kwon, VJ Lowe, AT Kendi, MS Bold, LC Pagliaro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading